ライフサイエンスコーパス: vitreoretinal

1 na and we show that PtchlacZ+/- mice exhibit vitreoretinal abnormalities resembling those found in BC

2 ill be useful in investigating the effect of vitreoretinal adhesion on ocular hemorrhage caused by in

3 erlie vitreous liquefaction and weakening of vitreoretinal adhesion.

4 T is highly sensitive to visualize posterior vitreoretinal and choroidal structures into a single ful

5 The societal costs associated with vitreoretinal and other ophthalmic interventions include

6 Many vitreoretinal and other ophthalmologic interventions con

7 e following conditions: continuous posterior vitreoretinal attachment (PVA), vitreomacular adhesion (

8 Inclusion criteria were complete vitreoretinal attachment, no ocular pathology other than

9 Primary vitreoretinal B-cell lymphoma and uveitis might be chara

10 authors speculate that the integrity of the vitreoretinal border is an important factor in preventin

11 January 2009 to December 2014, at 4 tertiary vitreoretinal centers in Italy were enrolled.

12 halmic data and operative information from 3 vitreoretinal centers were entered prospectively into an

13 ied 144 eyes of 72 consecutive patients in a vitreoretinal clinical practice, reviewing multimodal im

14 Vitreoretinal clinical practice.

15 In 37 patients, 65 eyes with CSC from 2 vitreoretinal clinical practices were imaged using ultra

16 T transformed the clinical management of the vitreoretinal conditions, iOCT has the potential to be a

17 Snowflake vitreoretinal degeneration (SVD, MIM 193230) is a develo

18 och syndrome, characterized by age-dependent vitreoretinal degeneration and occipital encephalocele.

19 ings provide an explanation for high myopia, vitreoretinal degeneration and retinal detachment seen i

20 mutation can cause SVD and further show that vitreoretinal degeneration can arise through mutations i

21 Snowflake vitreoretinal degeneration should be considered in the d

22 characterized by occipital skull defects and vitreoretinal degeneration.

23 se-region, suggests a novel pathogenesis for vitreoretinal degeneration.

24 However, distinguishing vitreoretinal diffuse large B-cell lymphoma from uveitis

25 Vitreoretinal diffuse large B-cell lymphoma is a rare di

26 trations of HGF/SF increase in proliferative vitreoretinal disease and increase in turn with increase

27 The field of vitreoretinal disease and surgery has seen tremendous gr

28 A panel of vitreoretinal disease experts was the foundation of the

29 omy allows patients who often have bilateral vitreoretinal disease to come to a stable postoperative

30 The role of HGF/SF in proliferative vitreoretinal disease was investigated.

31 plana vitrectomy surgery and the underlying vitreoretinal disease will allow the surgeon to address

32 y (OCT) has improved the care of adults with vitreoretinal disease, and OCT angiography (OCTA) is dem

33 control group (>50 years of age) without any vitreoretinal disease.

34 recting corneal astigmatism in patients with vitreoretinal diseases and cataract.

35 ent data on the economics of telemedicine in vitreoretinal diseases.

36 g the cost-effectiveness of telemedicine for vitreoretinal diseases.

37 emselves as specializing in the treatment of vitreoretinal diseases.

38 s review is to examine the macroeconomics of vitreoretinal diseases.

39 nvolved in the pathogenesis of PDR and other vitreoretinal diseases.

40 approach to the surgical management of this vitreoretinal disorder.

41 wngrowth, iridocorneal endothelial syndrome, vitreoretinal disorders, and penetrating keratoplasty.

42 wn to be present and active in proliferative vitreoretinal disorders, suggesting that Muller cells re

43 ity of Muller cells and its association with vitreoretinal disorders, we examined morphology, propaga

44 al tissue elastic modulus may have a role in vitreoretinal disorders.

45 ular developmental defects, including severe vitreoretinal dysplasia, optic nerve hypoplasia, persist

46 These results indicate that early bilateral vitreoretinal eye pathology coupled with skeletal fragil

47 In all cases, the primary surgeon was a vitreoretinal fellow.

48 tinal breaks and RD following primary PPV by vitreoretinal fellows is low and comparable to that of f

49 plana vitrectomy (PPV) is often performed by vitreoretinal fellows.

50 morbidities, presenting symptoms and vision, vitreoretinal findings, treatment regimens, culture data

51 tcomes were worse for patients who underwent vitreoretinal follow-up surgery, likely because of mecha

52 e also found in the ipsilateral vitreous and vitreoretinal interface (but not destructive chorioretin

53 of the major NO metabolite, nitrate, at the vitreoretinal interface (VRI) of normal and aged rat mod

54 hether an association between changes at the vitreoretinal interface (VRI), in particular traction (V

55 OCT or TD-OCT have similar ability to assess vitreoretinal interface abnormalities and outcomes of en

56 (OCT) protocol designed to evaluate formally vitreoretinal interface abnormalities on scans obtained

57 Eyes with vitreoretinal interface abnormalities or that had underg

58 There was no apparent damage of the vitreoretinal interface after unsuccessful pharmacologic

59 ght into the range of retinal defects at the vitreoretinal interface and fovea, which is not only use

60 use of rhegmatogenous retinal detachment and vitreoretinal interface disorders, as well as potential

61 Quantitative and morphologic vitreoretinal interface features were assessed reproduci

62 image modification process that enhances the vitreoretinal interface first and then the choroid, whil

63 ides wide-field 3-dimensional information of vitreoretinal interface in diabetic eyes.

64 trials, and can facilitate identification of vitreoretinal interface pathology during care of individ

65 The vitreoretinal interface, which often consisted of lamell

66 t fibronectin and laminin, components of the vitreoretinal interface.

67 thin the retina and is accentuated along the vitreoretinal interface.

68 societal cost perspective associated with a vitreoretinal intervention.

69 Vitreoretinal interventions account for only a small por

70 Vitreoretinal interventions are generally cost-effective

71 Most vitreoretinal interventions are very cost effective usin

72 arative effectiveness and cost-effectiveness vitreoretinal interventions assessed in the US healthcar

73 Most vitreoretinal interventions confer considerable patient

74 The majority of vitreoretinal interventions confer considerable value an

75 Vitreoretinal interventions have good to excellent compa

76 The average cost-utility of these vitreoretinal interventions is US$23 026/QALY (SD US$24

77 , and cost-utility analyses encompassing the vitreoretinal interventions of the following: (1) laser

78 est that ophthalmic interventions, including vitreoretinal interventions, are cost effective.

79 tive effectiveness and cost-effectiveness of vitreoretinal interventions, measured in quality-adjuste

80 ure was spent on ocular diseases and 0.3% on vitreoretinal interventions.

81 ngly used to study the cost-effectiveness of vitreoretinal interventions.

82 cine and its impact, or potential impact, on vitreoretinal interventions.

83 Not all lymphomas with vitreoretinal involvement represent primary intraocular

84 extracellular proteins that characterize the vitreoretinal junction (fibronectin, laminin) and vitreo

85 ent comparative effectiveness studies in the vitreoretinal literature.

86 associated with overall survival in primary vitreoretinal lymphoma (PVRL) and ocular adnexal (OA)-uv

87 The best treatment option for primary vitreoretinal lymphoma (PVRL) without signs of central n

88 assessed the frequency of MYD88 mutations in vitreoretinal lymphoma (VRL) and their diagnostic potent

89 udy included 17 diffuse large B-cell primary vitreoretinal lymphoma and 12 uveitis patients.

90 maging and ultimately diagnosed with primary vitreoretinal lymphoma and/or primary central nervous sy

91 The diagnosis of primary vitreoretinal lymphoma and/or primary central nervous sy

92 opathy, can precede the diagnosis of primary vitreoretinal lymphoma or primary central nervous system

93 Vitreoretinal lymphoma remains a clinical diagnostic cha

94 icroRNA-197, and microRNA-132 in the primary vitreoretinal lymphoma vitreous and higher microRNA-155,

95 had no history of lymphoma; the diagnosis of vitreoretinal lymphoma was followed by DLBCL after a lym

96 on in systemic lymphoma, mimicking a primary vitreoretinal lymphoma, is extremely rare.

97 Selected samples (primary vitreoretinal lymphoma, n = 3; uveitis, n = 3) were arra

98 luation in all patients with newly diagnosed vitreoretinal lymphoma.

99 kines are promising diagnostic biomarkers of vitreoretinal lymphoma.

100 prognosis is particularly poor compared with vitreoretinal lymphomas even in response to chemotherapy

101 The vitreoretinal manifestations include anterior uveitis, v

102 LRDI has not been applied to vitreoretinal ophthalmological problems previously.

103 Fifteen centers with both pediatric and vitreoretinal ophthalmologists participating in level 3

104 ed macular degeneration (AMD), without other vitreoretinal pathology.

105 The vitreoretinal pharmacokinetic profiles were similar betw

106 f culture-proven endophthalmitis in a single vitreoretinal practice over the course of 3 years and de

107 Vitreoretinal practice patterns changed significantly fr

108 ries at a single tertiary referral pediatric vitreoretinal practice.

109 ctive single-center case series at a private vitreoretinal practice.

110 CLINICAL RELEVANCE: To analyze vitreoretinal procedural trends, which may indicate stan

111 To analyze vitreoretinal procedural trends, which may indicate stan

112 identify the number of allowed services for vitreoretinal procedures and commonly used pharmacologic

113 his study was to identify changes in use for vitreoretinal procedures by measuring the number of allo

114 Vitreoretinal procedures grew 6-fold from 2000 to 2014.

115 itreal injections accounted for 0.55% of all vitreoretinal procedures in 2000 and increased to 87% in

116 e and 24 (37.5%) patients who had endoscopic vitreoretinal procedures initially before undergoing a c

117 been used successfully, temporarily, during vitreoretinal procedures.

118 cle highlights some of the current trends in vitreoretinal research that promise to be revolutionary

119 Based on recent advances in ongoing vitreoretinal research, the spectrum of treatable retina

120 OCT facilitates the detection of early vitreoretinal separation that indicates initial PVD.

121 negotiations between representatives of the Vitreoretinal Society of India (VRSI) and India's Centra

122 aterality of FH were recorded by 1 pediatric vitreoretinal specialist.

123 eolysis were reported in 15 patients by 7 US vitreoretinal specialists during the study period.

124 Expedited referral to vitreoretinal specialists is recommended for management

125 inopathy, two conditions commonly treated by vitreoretinal specialists, are projected to affect more

126 er diabetic vitrectomy, and subsequently the vitreoretinal surgeon attempted to spare the lens.

127 The vitreoretinal surgeon may consider rendering an eye nonp

128 t could provide enhanced information for the vitreoretinal surgeon.

129 ickness macular holes (MHs) is important for vitreoretinal surgeons and their patients.

130 There remains no consensus among vitreoretinal surgeons regarding the optimal management

131 This may enable vitreoretinal surgeons to benchmark their case-mix and o

132 These results may help vitreoretinal surgeons to benchmark their intraoperative

133 ertaken by specialized ocular oncologists or vitreoretinal surgeons with experience in managing this

134 experts (3 pediatric ophthalmologists and 6 vitreoretinal surgeons) participated in the study.

135 reoretinopathy (PVR) is a serious problem in vitreoretinal surgeries.

136 Adverse events were associated with vitreoretinal surgery and immunosuppression.

137 e predictability in patients with a previous vitreoretinal surgery can be as good as in uncomplicated

138 The role of iOCT in vitreoretinal surgery continues to be defined by active

139 A total of 20 of 739 eyes (2.7%) underwent vitreoretinal surgery for complications arising from cho

140 patients who subsequently required secondary vitreoretinal surgery for complications arising from suc

141 Inc, Irvine, CA) can improve the outcomes of vitreoretinal surgery for established proliferative vitr

142 review of consecutive patients who underwent vitreoretinal surgery for myopic traction maculopathy by

143 Only 2 eyes required vitreoretinal surgery for nonclearing vitreous hemorrhag

144 Patients who underwent vitreoretinal surgery had overall worse visual outcomes.

145 f 360 patients undergoing 27-gauge PPV for a vitreoretinal surgery indication.

146 Eyes undergoing 27 gauge PPV for a vitreoretinal surgery indication.

147 However, Cibis' contributions to vitreoretinal surgery only occupied the last 10 years of

148 Eyes with prior vitreoretinal surgery or laser or anti-vascular endothel

149 erative sickle retinopathy were managed with vitreoretinal surgery over a 12-year period at a single

150 l of 565 eyes were included in this study of vitreoretinal surgery performed from April 2011 to June

151 Fifty-eyes of 50 adults undergoing vitreoretinal surgery were enrolled.

152 Patients who underwent vitreoretinal surgery were randomized into 3 groups base

153 rom 13 sites where data on both cataract and vitreoretinal surgery were recorded on the same electron

154 The indications for vitreoretinal surgery were recorded, as were the locatio

155 n the US and 96% completed a fellowship (25% vitreoretinal surgery, 22% cornea and external disease,

156 ta recorded included phakic status, previous vitreoretinal surgery, and anterior chamber (AC) cells a

157 adjunct for clinical decision making during vitreoretinal surgery, and OCT angiography (OCTA) has pr

158 ative optical coherence tomography (iOCT) in vitreoretinal surgery, assess the current state-of-the a

159 xpanding the scope and improving outcomes in vitreoretinal surgery.

160 nometry are in excellent agreement following vitreoretinal surgery.

161 and 0.5% bupivacaine in patients undergoing vitreoretinal surgery.

162 its role in the modern era of microincision vitreoretinal surgery.

163 issociated) light, is redefining its role in vitreoretinal surgery.

164 1911-1965) was one of the pioneers of modern vitreoretinal surgery.

165 was recovered from 47 individuals undergoing vitreoretinal surgery: 16 had nonproliferative diabetic

166 Numerous vitreoretinal surgical conditions and procedures have be

167 h removal of silicone oil without additional vitreoretinal surgical intervention at 6 months.

168 Vitreoretinal surgical repair for this condition is succ

169 Continuous refinements in vitreoretinal surgical techniques and an increasing numb

170 Vitreoretinal surgical techniques for the management of

171 With advances in vitreoretinal surgical techniques, however, the indicati

172 With proper vitreoretinal surgical techniques, posteriorly dislocate

173 ll further expand the horizon of iOCT in the vitreoretinal surgical theater.

174 Vitreoretinal symptoms of DLBCL in patients with systemi

175 Modified vitreoretinal techniques also have been developed, allow

176 s not unusual to require relatively advanced vitreoretinal techniques to achieve long-term surgical s

177 omitantly with more experience using various vitreoretinal techniques to manage these complicated cas

178 eral granulomas (57.1%), vasculitis (57.1%), vitreoretinal traction (57.1%), and chronic macular edem

179 Previous studies have suggested that vitreoretinal traction (VRT) may contribute to the progr

180 pithelium include typical findings of peaked vitreoretinal traction and retinal disorganization with

181 hes a new reproducible technique to quantify vitreoretinal traction during vitrectomy and demonstrate

182 Vitreoretinal traction was found in 39 eyes (40%).

183 d macular edema, central serous retinopathy, vitreoretinal traction, and age-related macular degenera

184 c traction maculopathy, epiretinal membrane, vitreoretinal traction, optic or scleral pit, or advance

185 ing into zone III (p = 0.023) and associated vitreoretinal trauma (p = 0.008).

186 posterior to rectus insertion and associated vitreoretinal trauma can adversely affect the outcome in

187 erative diabetic retinopathy at 16 different vitreoretinal units in the United Kingdom.

188 BRI or VEH was administered by gavage, and vitreoretinal vascular endothelial growth factor (VEGF)

189 findings, retinal ganglion cell (RGC) count, vitreoretinal vascular endothelial growth factor (VEGF)

190 BRI produced marked decreases in vitreoretinal VEGF and inhibition of BRB breakdown in di

191 of ischemia responsible for upregulation of vitreoretinal VEGF and thus reduce vascular leakage and

192 sure to high oxygen significantly attenuated vitreoretinal VEGF concentrations, retinal vascular leak

193 BRI treatment significantly attenuated vitreoretinal VEGF concentrations, retinal vascular leak

194 diabetic animals but significantly decreased vitreoretinal VEGF expression and BRB breakdown to level

195 tic rats demonstrated significantly elevated vitreoretinal VEGF expression, vitreal glutamate concent

196 for all), despite negligible differences in vitreoretinal VEGF levels at the time of evaluation (P >

197 atment also significantly decreased elevated vitreoretinal VEGF protein levels and retinal BRB leakag

198 retinopathy with neurodegeneration, elevated vitreoretinal VEGF protein levels, and increased BRB bre

199 Vitreoretinal VEGF protein, vitreal glutamate, and BRB b